Stay updated with breaking news from Nasdaq Blph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) was the target of a large increase in short interest in May. As of May 31st, there was short interest totalling 347,000 shares, an increase of 44.3% from the May 15th total of 240,400 shares. Based on an average trading volume of 614,200 shares, the days-to-cover ratio is […]
Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) had its price target reduced by HC Wainwright from $30.00 to $2.00 in a report issued on Tuesday, The Fly reports. HC Wainwright also issued estimates for Bellerophon Therapeutics’ Q4 2023 earnings at ($0.45) EPS, FY2023 earnings at ($1.11) EPS, FY2024 earnings at ($1.53) EPS, FY2025 earnings at ($0.78) […]
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) major shareholder Life Science Opportu Puissance sold 134,421 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $0.83, for a total value of $111,569.43. Following the completion of the sale, the insider now owns […]
Brookline Capital Management cut shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) from a buy rating to a hold rating in a report published on Monday morning, PriceTargets.com reports. Other equities analysts have also issued reports about the stock. StockNews.com upgraded shares of Bellerophon Therapeutics from a sell rating to a hold rating in a […]
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) VP Bobae Kim sold 9,455 shares of the firm’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $10.00, for a total transaction of $94,550.00. Following the completion of the transaction, the vice president now directly owns 1,723 shares in […]